Search
Main Menu
Main Content
Fermer
Choose language
FR
EN
Accessibility
Change contrast :
Standards
Reinforced
icone
HAS profile
Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest
International relations and projects
Publications
English content
Medicines
Opinions on medical devices
INAHTA briefs
French website
Chercher
Recherche
icone plus
English content
Les recommandations et guides
Les médicaments
Les actes professionnels
Les dispositifs médicaux
Les médecins accrédités
Les articles d'information
Les établissements de santé
Chercher
My account
My account
Email alert Subscription
Newsletter Subscription
My search
Refresh
Please fill in your email address to retrieve your email alerts subscriptions.
New subscription
Please fill in your email address to retrieve your newsletter subscriptions.
You do not have a saved search
Mon Compte
Sélection
No element in selection
Favoris
Sélection
Établissements de santé
Contact
Abonnez-vous aux actualités
1 result
Active substance : omalizumab
Date : du 23/11/2019 au 23/11/2023
OK
Chercher
Filter
Topic
Economics and public health
(1)
Plus ...
Health economics
(1)
Diagnostic and therapeutic techniques
(1)
Plus ...
Drug therapy
(1)
Diseases and conditions
(1)
Plus ...
Respiratory tract diseases
(1)
Plus ...
Pulmonary and pleural diseases
(1)
Bronchial diseases
(1)
Skin and connective tissue diseases
(1)
Immune system diseases
(1)
Plus ...
Allergy
(1)
Population groups
(1)
Plus ...
Paediatrics
(1)
Content type
Drugs, devices and medical acts
(1)
Plus ...
Medicine
(1)
Date
Last five years
(1)
Language
Français
(1)
Active substance
omalizumab
(1)
More filter
Save your search
Search Export
Drugs, devices and medical acts
- 1 result
XOLAIR
Medicine
- Posted on 18/9/2024
Add to
my selection
Français
English
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
tAMemc48LxBUeSN5